# First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

> **NCT06727981** · — · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 500 (estimated)

## Conditions studied

- Advanced Gastric Cancer
- Locally Advanced Gastric Carcinoma

## Interventions

- **DRUG:** ICI plus Chemothearpy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06727981
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2028-01-15
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06727981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06727981, "First-Line and Neoadjuvant Immunotherapy for Gastric Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06727981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*